These studies suggest the potential for p53 activation by inhibition of MDM2 as a novel CML therapy, and a potential therapeutic benefit of p53 activation alone or as a sensitizer to other therapeutic agents. This evidence concerns the gene TP53 and chronic myelogenous leukemia, BCR-ABL1 positive.